Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups

doi:10.1016/0140-6736(93)90416-E

The Lancet

Volume 341, Issue 8846, 13 March 1993, Pages 643-647

https://doi.org/10.1016/0140-6736(93)90416-E Get rights and content

Abstract

Neutrophils have been implicated in the pathogenesis of the adult respiratory distress syndrome (ARDS). We have measured concentrations of the neutrophil attractant interleukin-8 in blood and bronchoalveolar lavage fluid (BAL) from patients at risk of ARDS.

We studied 29 patients from three groups at risk of developing ARDS: multiple trauma (n=16), perforated bowel (n=6), and pancreatitis (n=7). ARDS developed in 7 of these patients. Interleukin-8 in BAL and blood samples taken on initial hospital presentation was measured by a sandwich enzyme-linked immunosorbent assay. The mean BAL interleukin-8 concentration was significantly higher for the patients who subsequently progressed to ARDS than for the non-ARDS group (3·06 [SE 2·64] vs 0·053 [0·010] ng/mL, p=0·0006). There was no difference between the groups in plasma interleukin-8 (6·23 [2·60] vs 5·12 [2·22] ng/mL, p=0·31). Immunocytochemistry suggested that the alveolar macrophage is an important source of interleukin-8 at this early stage in ARDS development.

This study provides evidence of a relation between the presence of interleukin-8 in early BAL samples and the development of AR DS. The early appearance of interleukin-8 in BAL of patients at risk of ARDS may be an important prognostic indicator for the development of the disorder and reinforces the likely importance of neutrophils and the effects of their accumulation and activation in the pathogenesis of many cases of ARDS.

References (30)

Gm Rocker et al.
Diagnostic criteria for adult respiratory distress syndrome: time for reappraisal
Lancet
(1989)
Je Rinaldo et al.
Mechanisms and mediators of the adult respiratory distress syndrome
Clin Chest Med
(1990)
Rm Strieter et al.
Human neutrophils exhibit disparate chemotactic factor gene expression
Biochem Biophys Res Commun
(1990)
H. Gregory et al.
Structure determination of a human lymphocyte derived neutrophil activating peptide (LYNAP)
Biochem Biophys Res Commum
(1988)
Pd McNaughton et al.
Management of adult respiratory distress syndrome
Lancet
(1992)
Tl Petty et al.
The adult respiratory distress syndrome
Je Repine et al.
Neutrophils and adult respiratory distress syndrome: two interlocking perspectives in 1991
Am Rev Respir Dis
(1991)
Je Rinaldo et al.
Adult respiratory distress syndrome: changing concepts of lung injury and repair
N Engl J Med
(1982)
Fj Warshawski et al.
Abnormal neutrophil-pulmonary interaction in the adult respiratory distress syndrome
Am Rev Respir Dis
(1986)
Je Weiland et al.
Lung neutrophils in the adult respiratory distress syndrome: clinical and pathophysiological significance
Am Rev Respir Dis
(1986)

P. Christner et al.

Collagenase in the lower respiratory tract of patients with the adult respiratory distress syndrome

Am Rev Respir Dis

(1985)

Ej Miller et al.

Elevated levels of NAP-1/ interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality

Am Rev Respir Dis

(1992)

Gl Larsen et al.

Mediators of inflammation

Annu Rev Immunol

(1983)

Sl Kunkel et al.

Interleukin-8: the major neutrophil chemotactic factor in the lung

Exp Lung Res

(1991)

Cited by (626)

Carnosic acid inhibits reactive oxygen species-dependent neutrophil extracellular trap formation and ameliorates acute respiratory distress syndrome
2023, Life Sciences
Infiltration of activated neutrophils into the lungs is a hallmark of acute respiratory distress syndrome (ARDS). Neutrophilic inflammation, particularly neutrophil extracellular traps (NETs), is proposed as a useful target for treating ARDS. Carnosic acid (CA) is a food additive; however, its anti-neutrophilic activity in the treatment of ARDS has not been well established. The hypothesis of present study is to confirm that CA alleviates ARDS by suppressing neutrophilic inflammation and oxidative damage.
Generation of superoxide anions and reactive oxygen species (ROS), induction of elastase degranulation, and formation of NETs by human neutrophils were assayed using spectrophotometry, flow cytometry, and immunofluorescent microscopy. Immunoblotting was performed to determine the cellular mechanisms involved. Cell-free radical systems were used to test antioxidant activities. The therapeutic effect of CA was evaluated in a lipopolysaccharide (LPS)-induced ARDS mouse model.
CA greatly reduced superoxide anion production, ROS production, elastase release, cluster of differentiation 11b expression, and cell adhesion in activated human neutrophils. Mechanistic studies have demonstrated that CA suppresses phosphorylation of extracellular regulated kinase and c-Jun N-terminal kinase in activated neutrophils. CA effectively scavenges reactive oxygen and nitrogen species, but not superoxide anions. This is consistent with the finding that CA is effective against ROS-dependent NET formation. CA treatment significantly improved pulmonary neutrophil infiltration, oxidative damage, NET formation, and alveolar damage in LPS-induced mice.
Our data suggested the potential application of CA for neutrophil-associated ARDS therapy.
Association of the C-terminal 42-peptide fragment of alpha-1 antitrypsin with the severity of ARDS: A pilot study
2023, Clinical Biochemistry
Acute respiratory distress syndrome is a life-threatening condition with a hospital mortality rate of up to 40%. Biomarkers related to the pathophysiology of ARDS may not only identify patients at risk but may also serve as potential therapeutic targets. This study examined the association between the proteolytic C-terminal 42-peptide fragment of alpha-1 antitrypsin and ARDS severity.
The 42-peptide fragment and interleukin-6 levels were measured in 21 patients with mild-to-moderate ARDS and 47 patients with moderate-to-severe ARDS on days 1, 3, and 5 after diagnosis/admission to the intensive care unit. To elucidate the association between both biomarkers and the PaO₂/FiO₂ ratio, the concentrations of both biomarkers were compared between the two groups, and a multivariate regression analysis was performed.
The concentrations of both biomarkers were higher in patients with moderate-to-severe ARDS. While the PaO₂/FiO₂ ratio increased from day 1 to day 3, the concentrations of both biomarkers decreased. Multivariate regression analysis revealed negative associations between the PaO₂/FiO₂ ratio and both the C-terminal 42-peptide of alpha-1 antitrypsin and interleukin-6 on day 1 (beta: −0.138, p = 0.052; beta: −0.096, p = 0.004) and on day 3 (beta: −0.157, p = 0.045; beta: −0.106, p = 0.043).
The C-terminal 42-peptide of alpha-1 antitrypsin is a new biomarker associated with ARDS severity. Its predictive value in identifying patients at risk of developing moderate-to-severe ARDS must be investigated in additional, independent prospective studies.
Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes
2022, Cell Reports
SARS-CoV-2-infected subjects are generally asymptomatic during initial viral replication but may suffer severe immunopathology after the virus has receded and monocytes have infiltrated the airways. In bronchoalveolar lavage fluid from severe COVID-19 patients, monocytes express mRNA encoding inflammatory mediators and contain SARS-CoV-2 transcripts. We leverage a human small airway model of infection and inflammation, whereby primary blood monocytes transmigrate across SARS-CoV-2-infected lung epithelium to characterize viral burden, gene expression, and inflammatory mediator secretion by epithelial cells and monocytes. In this model, lung-infiltrating monocytes acquire SARS-CoV-2 from the epithelium and upregulate expression and secretion of inflammatory mediators, mirroring in vivo data. Combined use of baricitinib (Janus kinase inhibitor) and remdesivir (nucleoside analog) enhances antiviral signaling and viral clearance by SARS-CoV-2-positive monocytes while decreasing secretion of proneutrophilic mediators associated with acute respiratory distress syndrome. These findings highlight the role of lung-infiltrating monocytes in COVID-19 pathogenesis and their importance as a therapeutic target.
Resistin Pathway as Novel Mechanism of Post-lung Transplantation Bronchial Stenosis
2024, Journal of Bronchology and Interventional Pulmonology
Indole-3-carbinol attenuates lipopolysaccharide-induced acute respiratory distress syndrome through activation of AhR: role of CCR2+ monocyte activation and recruitment in the regulation of CXCR2+ neutrophils in the lungs
2024, Frontiers in Immunology
Role of biomarkers and molecular signaling pathways in acute lung injury
2024, Fundamental and Clinical Pharmacology

View all citing articles on Scopus

View full text

ARTICLESInterleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups

Abstract

Lancet

Clin Chest Med

Biochem Biophys Res Commun

Biochem Biophys Res Commum

Management of adult respiratory distress syndrome

Lancet

The adult respiratory distress syndrome

Neutrophils and adult respiratory distress syndrome: two interlocking perspectives in 1991

Am Rev Respir Dis

Adult respiratory distress syndrome: changing concepts of lung injury and repair

N Engl J Med

Abnormal neutrophil-pulmonary interaction in the adult respiratory distress syndrome

Am Rev Respir Dis

Lung neutrophils in the adult respiratory distress syndrome: clinical and pathophysiological significance

Am Rev Respir Dis

Collagenase in the lower respiratory tract of patients with the adult respiratory distress syndrome

Am Rev Respir Dis

Elevated levels of NAP-1/ interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality

Am Rev Respir Dis

Mediators of inflammation

Annu Rev Immunol

Interleukin-8: the major neutrophil chemotactic factor in the lung

Exp Lung Res

ARTICLES
Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups